Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of Leo Lee as an independent non-executive director of Regeneus with effect from December.
Regeneus Ltd (ASX:RGS) provides the Company's Chairman's address to shareholders and CEO presentation at 2017 Annual General Meeting.
Regeneus Ltd (ASX:RGS) provides the Company's Presentation on Japan First Strategy at Ord Minnett.
Regeneus Ltd (ASX:RGS) , a clinical-stage regenerative medicine company, today announced that a preclinical post-operative pain study has shown that topical application of Sygenus, has significantly greater and longer lasting analgesic effect than an injection of morphine.
The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.6m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2017.
Regeneus Ltd (ASX:RGS) CEO John Martin talks on the release of the financial results following the company's significant progress with Japanese partner Asahi Glass Ltd (AGC) (TYO:5201)
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Full-Year Report for the 12 months ending 30 June 2017.
Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2017.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for a patent covering the composition, manufacture and use of the secretion stem cell technology platform, known as Sygenus, to treat acne. We recently informed the market of the new name for the secretions platform in our Q2 2017 Update.
Appendix 4G and Corporate Governance Statement
Appendix 3Z - Final Director's Interest Notice
Appendix 4D and Half-Year Report
